The Global Health Body Raises Concern Over Critical Lack of Obesity Jabs
Less than 10% of people who could benefit from weight-loss injections such as Wegovy can access them, warns the World Health Organization as it releases its first advice on the therapies.
Given in excess of 1,000,000,000 people worldwide currently obese, it is urging broader and more equitable availability to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 could be obese by 2030 if no action is taken.
"The latest guidelines affirms that obesity is a long-term condition that can be managed with comprehensive and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are key barriers to widespread access to the jabs that can aid individuals in losing substantial weight, says the body.
GLP-1 Therapy Supply Crisis
Despite the current most optimistic outlook, the supply of such drugs could only cover approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline urges governments and firms to increase availability, through approaches such as voluntary licensing.
The intellectual property rights on a key compound – the main ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026.
The Way Weight-Loss Jabs Function
The injections replicate a natural hormone to delay gastric emptying, curb appetite and boost the sense of being full so users reduce food intake.
People usually see weight reduction in the initial weeks of beginning the regular doses.
Evidence points to people may see weight return within a year of halting the drug, because their usual food cravings resume.
To be above a healthy weight elevates your risk for contracting diseases, like type 2 diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity affects people in every country and was associated with 3.7 million deaths worldwide in 2024, per the health agency.
